Hull University Teaching Hospitals NHS Trust
Hull, HU3 2JZ, United Kingdom
Location status: Recruiting
NCT Number: NCT07270575
RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.
These drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Hull, HU3 2JZ, United Kingdom
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Esprit BTK™ is a bioresorbable vascular scaffold designed for arteries below the knee. It provides temporary support to keep the vessel open while releasing everolimus-an antiproliferative drug that helps prevent excessive tissue growth and reduces the risk of restenosis. As the scaffold delivers the medication, it gradually dissolves, potentially lowering long-term risks associated with permanent stents.
Other names: Drug-eluting resorbable scaffold
Time frame: 12 months
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.
Time frame: Until the end of the follow-up period of 3 years
Defined as the time between first index procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.
Time frame: 12, 24, and 36 months
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss.
Time frame: 12, 24, and 36 months
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening).
Time frame: 12 and 24 months
Defined as absence of any amputation of the target limb (above ankle).
Time frame: Until the end of the follow-up period of 3 years
Defined as time between first index procedure and amputation of the target limb, minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the index procedure).
Time frame: Until the end of the follow-up period of 3 years
Defined as the time between the first index procedure and death of any cause.
Time frame: Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD.
Time frame: Within 30 days after the index procedure
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe.
Time frame: 6 months for MALE; Within 30 days after the index procedure for POD
MALE include above-ankle amputation in the index limb, major re-intervention on the index limb at 6 months and POD includes perioperative (30-day) mortality.
Time frame: 12, 24, and 36 months
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease.
Time frame: 12, 24, and 36 months
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion.
Time frame: 12, 24, and 36 months
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization.
Time frame: Immediately upon procedure completion
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure.
Interested in participating?
Request InfoCardiovascular and Interventional Radiological Society of Europe
Other
Acronym: RESCUE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07270562
Arterial Occlusive Diseases, Arteriosclerosis
Hull, United Kingdom
View Trial DetailsNCT07472049
Arterial Occlusive Diseases, Arteriosclerosis
Edinburgh, Midlothian, United Kingdom
View Trial DetailsNCT06979284
Arterial Occlusive Diseases, Arteriosclerosis
Hamilton, Canada
View Trial DetailsNCT07465627
Arterial Occlusive Diseases, Arteriosclerosis
Graz, Austria
View Trial Details